Pharmacology of cannabis and its receptor;Cannabis og cannabinoider som legemidler

Tidsskrift for den Norske Laegeforening

Volumn 127, Issue 5, 2007, Pages 579-582

  Khiabani, Hassan Z ^a   Mørland, Jørg ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; PIPERIDINE DERIVATIVE; PSYCHOTROPIC AGENT; PYRAZOLE DERIVATIVE; RIMONABANT; TETRAHYDROCANNABINOL;

ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PSYCHOSIS; RISK FACTOR;

CANNABINOIDS; CANNABIS; COGNITION DISORDERS; HUMANS; PIPERIDINES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; PYRAZOLES; RECEPTORS, CANNABINOID; RISK FACTORS; TETRAHYDROCANNABINOL;

EID: 33847679546     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Abel EL. A comprehensive guide to the cannabis literature. Westport, CT: Greenwood Press, 1979.
2. Mechoulam R, Gaoni Y. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965; 21: 1223-9.
3. Mechoulam R, Gaoni Y. The absolute configuration of delta-1- tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 1967; 12: 1109-11.
4. Devane WA, Dysarz FA, Johnson MR et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
5. Howlett AC, Bidaut-Russell M, Devane WA et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-3.
6. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16: 276-82.
7. Heishman SJ, Stitzer ML, Yingling JE. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 1989; 34: 173-9.
8. Azorlosa JL, Heishman SJ, Stitzer ML et al. Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 1992; 261: 114-22.
9. Ohlsson A, Lindgren JE, Wahlen A et al. Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 1982; 9: 6-10.
10. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992; 16: 283-90.
11. Perez-Reyes M, Lipton MA, Timmons MC et al. Pharmacology of orally administered 9 -tetrahydrocannabinol. Clin Pharmacol Ther 1973; 14: 48-55.
12. Wall ME, Sadler BM, Brine D et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983; 34: 352-63.
13. Smith-Kielland A. Urinary excretion of 11-nor-9-carboxy-Delta9- tetrahydrocannabinol: a case with an apparent long terminal half-life. Scand J Clin Lab Invest 2006; 66: 169-71.
14. Lafolie P, Beck O, Blennow G et al. Importance of creatinine analyses of urine when screening for abused drugs. Clin Chem 1991; 37: 1927-31.
15. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002; 22: 4720-7.
16. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
17. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond ) 2006; 30 (suppl 1): S13-8.
18. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
19. Devane WA, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 1994; 91: 6698-701.
20. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
21. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999; 65: 573-95.
22. Di Marzo V, Breivogel CS, Tao Q et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44.
23. Di Marzo V, Bisogno T, De Petrocellis L et al. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem 1999; 6: 721-44.
24. Ottani A, Giuliani D. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001; 7: 131-45.
25. Wilson RG, Jr., Tahir SK, Mechoulam R et al. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int 1996; 20: 147-57.
26. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
27. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65: 715-23.
28. Tramer MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16-21.
29. Campbell FA, Tramer MR, Carroll D et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-6.
30. Karst M, Salim K, Burstein S et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-62.
31. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 7: 607-15.
32. Blake DR, Robson P, Ho M et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford ) 2006; 45: 50-2.
33. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006; 40: 251-60.
34. Ramirez BG, Blazquez C, Gomez del Pulgar T et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-13.
35. Iuvone T, Esposito G, Esposito R et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004; 89: 134-41.
36. Lastres-Becker I, Molina-Holgado F, Ramos JA et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005; 19: 96-107.
37. Huestis MA, Gorelick DA, Heishman SJ et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-8.
38. Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
40. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci 1995; 56: 2119-26.
41. Solowij N, Monterrubio S. Cognitive and neuropsychiatric consequences of endocannabinoid signaling dysfunction. Neuropsychopharmacology 2006; 31: 471-2.
42. Fletcher JM, Page JB, Francis DJ et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 1996; 53: 1051-7.
43. Messinis L, Kyprianidou A, Malefaki S et al. Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006; 66: 737-9.
44. Pope HG jr., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 275: 521-7.
45. Pope HG jr., Gruber AJ, Hudson JI et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15.
46. Solowij N, Stephens RS, Roffman RA et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-31.
47. Block RI, O'Leary DS, Hichwa RD et al. Cerebellar hypoactivity in frequent marijuana users. Neuroreport 2000; 11: 749-53.
48. Block RI, O'Leary DS, Hichwa RD et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72: 237-50.
49. Arseneault L, Cannon M, Witton J et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-7.
50. Arseneault L, Cannon M, Poulton R et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-3.
51. Zammit S, Allebeck P, Andreasson S et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
52. Helseth V, Lykke-Enger T, Aamo TO et al. Rusmiddelscreening av pasienter i alderen 17-40 år innlagt med psykose. Tidsskr Nor Lægeforen 2005; 125: 1178-80.
53. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306-13.
54. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330: 11.
55. Pedersen W. Stein, bønne, rev. Tidsskr Nor Lægeforen 2005; 125: 3388.